• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

Kolmar Korea Expands Production Capacity: Reasons for Optimism in the New Year Despite Industry Uncertainty

김나영 기자

steaming@fntimes.com

기사입력 : 2025-01-13 16:35

Last year, 120% of plants operated at full capacity... All-out effort to expand production bases in Sejong and North America

Panoramic view of Kolmar Korea headquarters. / Photo = Kolmar Korea

Panoramic view of Kolmar Korea headquarters. / Photo = Kolmar Korea

[Korea Financial Times, Kim Nayoung] Kolmar Korea(CEO Choi Hyun-gyu) is focusing on increasing productivity as it continues to expand factories at home and abroad. The company's increased production capacity is expected to serve as an earnings shield as the industry is facing a challenging year due to the high exchange rate.

According to a disclosure by the Financial Supervisory Service on the 13th, Kolmar Korea's factory utilization rate was 120.3% as of the third quarter of last year, exceeding its capacity. This was due to a rush of orders as the company exported more K-beauty products.

A Kolmar Korea official emphasized, “Last year, the factory’s operating rate exceeded 100% due to increased exports,” and “We are currently focusing on increasing productivity by expanding our factory facilities domestically and internationally.”

As additional orders are hard to come by, Kolmar Korea is tightening the reins on expanding its capacity (CAPA). The company plans to put the newly expanded Sejong 1 plant into full operation in the first half of this year. The expansion is expected to increase the company's cosmetics production capacity by more than 20 percent.

Securities analysts expect the company's increased production capacity to drive sales this year. “The domestic CAPA will increase by more than 20 percent this year, adding to the effect of the expansion,” said Park Eun-jung, a researcher at Hana Securities. ”The company is expected to respond smoothly to the increase in orders this year as its production capacity is steadily expanding.”

“With the completion of the line expansion at the Sejong plant, the company has secured an annual CAPA of 5.3 billion units,” said Jeong Jeong-sol, a researcher at Daeshin Securities, adding, ”Growth is expected to continue this year.”

Overseas production facilities will also see significant improvements this year. Kolmar Korea plans to complete its second U.S. plant in the first half of this year, raising the capacity utilization rate of its North American production facilities from 180 million to 300 million. The recent influx of new customers in the North American market has spurred the company to expand its local production capacity.

The expansion of domestic and international CAPA is raising expectations for Korea Kolmar's performance even as distribution costs have increased this year due to Trump's second term tariff policy and high exchange rates.

As a cosmetics ODM, the recent rise in the exchange rate is weighing on the company. The company imports major ingredients for cosmetics, such as palm oil and glycerin, from overseas. As of the third quarter of last year, the consolidated cost of sales ratio was 71.4%, which is a high proportion of raw materials.

However, this year's increase in orders and production from overseas customers is expected to offset the exchange rate burden to some extent. “Hankook Kolmar's U.S. subsidiary is expected to post high sales growth (55% year-on-year) due to the influx of new local customers, and its U.S. Plant 1 is expected to turn profitable,” said Jeong Jeong-sol. He also forecasts that the company's consolidated sales will reach KRW 2.7 trillion this year, up 11% from last year, and operating profit will increase 30% to KRW 270 billion (10% operating margin).

An industry insider said, “The recent increase in the exchange rate has increased the burden on companies that are highly dependent on importing raw materials,” adding, “Overseas subsidiaries are strengthening their global market operations as they trade in dollars.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 LG Chem Petrochemicals Face Losses Despite NCC Restart; Advanced Materials Recovering Petrochemicals is once again LG Chem’s main concern. While earnings at its battery subsidiary and advanced materials business are improving, its petrochemicals division, which returned to profit in the first half, is expected to slip back into the red in the second half. The No. 2 naphtha cracking center (NCC) plant in Yeosu, idled for about six months, has resumed operations. But a profit recovery looks difficult as the negative inventory lag effect from falling feedstock prices and higher logistics costs weigh on results.According to financial data provider FnGuide on the 22th, the consensu 2 Hanwha Systems Raises KRW 3.4 Trillion as It Winds Down ‘Bridge’ Role in Hanwha Ocean Deal Hanwha Systems is raising KRW 3.4 trillion through a price return swap (PRS) on its Hanwha Ocean shares and the sale of its stake in the Philly shipyard in the United States. Both assets came out of Hanwha Systems’ efforts to back the Hanwha Group’s push to strengthen its shipbuilding business. The company is now expected to end its “bridge” role and concentrate on strengthening its core business through capital reallocation.According to the investment banking (IB) industry on Oct. 20, Hanwha Systems recently decided to transfer all 22,169,660 of its Hanwha Ocean common shares to Kiwoom Se 3 Hanmi Pharm Hit by Shareholder Feud, Rights Return; Next Obesity Drug Key to Rebound Hanmi Pharm is facing a double blow, a dispute among its major shareholders and the return of rights to a key pipeline asset, and has slipped into a valuation discount.While solid core profitability provides a cushion, further out-licensing of follow-up obesity drugs and a resolution of governance risk are expected to be the main turning points for a revaluation.Inheritance Tax Sparked the Feud, Now a KRW 60 Billion LawsuitHanmi Pharmaceutical Group’s operating environment is clouded from every direction, industry sources said on Oct. 18. The governance risk began after the death of founder L
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'
환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11
[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략

FT도서

더보기